New drug combo could simplify breast cancer treatment for younger women

NCT ID NCT07159451

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether the drug elacestrant alone works as well as elacestrant combined with a drug that suppresses ovarian function (leuprorelin) in premenopausal women with early-stage, hormone-receptor-positive breast cancer. The study involves 140 women who will take the medication for 4 weeks before their scheduled breast surgery. Researchers will measure changes in a tumor growth marker (Ki67) to see how well the drugs are working.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
elacestrant (a hormone-blocking drug) and leuprorelin (a drug that temporarily stops ovarian function)
What this could lead to
If successful, this could show that elacestrant alone is as effective as combining it with ovarian suppression, potentially offering a simpler treatment option for premenopausal women with early-stage breast cancer.
What could go wrong
This is a small, early-phase study with only 140 participants, and it measures a biomarker (Ki67) rather than long-term outcomes like survival. The results may not translate to better cancer control or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gustave Roussy

    RECRUITING

    Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.